EMA
The European Medicines Agency (EMA) is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. It began operating in 1995.
Business & Industry
- Consignment of 30 million hydroxychloroquine tablets ships to US Department of Health and Human Services
- Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation
- Amgen and the Amgen Foundation commit up to $12.5 million to support COVID-19 relief efforts
- Roche response to COVID-19 pandemic
- AstraZeneca to donate 9 million face masks to support healthcare workers around the world in the fight against COVID-19
Research & Development
- FDA approves first plasma therapy for Houston Methodist COVID-19 patient
- Experimental AI tool predicts which COVID-19 patients develop respiratory disease
- Nafamostat is expected to prevent the transmission of new coronavirus infection (COVID-19)
- Singapore modelling study estimates impact of physical distancing on reducing spread of COVID-19
- CAR macrophages go beyond T cells to fight solid tumors
- Vivli to launch a portal for sharing data from COVID-19 trials
- Understanding how COVID-19 affects children vital to slowing pandemic
Conferences & Events
- Pre-Filled Syringes West Coast 2021
- Pre-Filled Syringes East Coast Conference 2020
- SMi's 4th Annual Pharmaceutical Microbiology West Coast
- SMi's 20th Annual Pain Therapeutics Conference 2020
- SMi's 3rd Annual Pharmaceutical Microbiology East Coast
- SMi's 22nd Annual Superbugs & Superdrugs Conference 2020
- SMi Presents the 3rd Annual Conference: Injectable Drug Delivery 2020
Regulatory Affairs
- The FDA is facilitating access to convalescent plasma collected from recovered COVID-19 patients
- FDA continues to facilitate development of COVID-19 treatments
- FDA and FTC warn seven companies selling fraudulent products that claim to treat or prevent COVID-19
- FDA approves new treatment for adults with Cushing's disease
- FDA approves first generic of Daraprim